Global Sulphonamides Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sulphonamides Market Research Report 2024
Sulfonamides (sulphonamides) are a group of man-made (synthetic) medicines that contain the sulfonamide chemical group. They may also be called sulfa drugs. Many people use the term sulfonamide imprecisely to refer only to antibiotics that have a sulfonamide functional group in their chemical structure.
According to Mr Accuracy reports’s new survey, global Sulphonamides market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Sulphonamides market research.
Key manufacturers engaged in the Sulphonamides industry include Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Bayer AG, GlaxoSmithKline, King Pharmaceuticals, Mylan Pharmaceuticals, Novartis International AG, Pfizer and Par Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Sulphonamides were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Sulphonamides market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sulphonamides market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Abbott Laboratories
Boehringer Ingelheim Pharmaceuticals
Bayer AG
GlaxoSmithKline
King Pharmaceuticals
Mylan Pharmaceuticals
Novartis International AG
Pfizer
Par Pharmaceutical
Roche Holding AG
Sanofi Aventis
Stiefel Laboratories
Segment by Type
Orally Absorbable Sulfonamide
Orally Non Absorbable Sulfonamide (sulfasalzine, osalazine)
Topical Agents (Silver sulfadiazine, sulfacetamide, mafenide)
Skin Infections
Gastro Intestinal Tract (GIT) Infection
Meningitis
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Sulphonamides report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Sulphonamides market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Sulphonamides market research.
Key manufacturers engaged in the Sulphonamides industry include Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Bayer AG, GlaxoSmithKline, King Pharmaceuticals, Mylan Pharmaceuticals, Novartis International AG, Pfizer and Par Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Sulphonamides were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Sulphonamides market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sulphonamides market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbott Laboratories
Boehringer Ingelheim Pharmaceuticals
Bayer AG
GlaxoSmithKline
King Pharmaceuticals
Mylan Pharmaceuticals
Novartis International AG
Pfizer
Par Pharmaceutical
Roche Holding AG
Sanofi Aventis
Stiefel Laboratories
Segment by Type
Orally Absorbable Sulfonamide
Orally Non Absorbable Sulfonamide (sulfasalzine, osalazine)
Topical Agents (Silver sulfadiazine, sulfacetamide, mafenide)
Segment by Application
Skin Infections
Gastro Intestinal Tract (GIT) Infection
Meningitis
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Sulphonamides report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source